Last, combinatorial treatment with a conventional cytotoxic agent (5-FU) and an HDAC6 inhibitor (Tubastatin A) may offer novel potential therapeutic options for CRC patients. The gene discussed is HDAC6; the disease is colorectal carcinoma.